ROCKVILLE, Md., Dec. 13, 2016 (GLOBE NEWSWIRE) --
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today provided an update on several of the Company's product candidates and technology platforms.
"At today's R&D Day, MacroGenics highlighted the continued progress our team is making to advance our growing portfolio of potential treatment options for patients with cancer, autoimmune disorders and infectious diseases," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "Today, we reviewed our expanded strategy for pursuing a balanced approached across novel and validated targets to develop three immuno-oncology franchises centered around HER2, B7-H3 and PD-1. This approach underscores our belief that cancer patients may significantly benefit from combinatorial and multi-specific strategies that are directly addressed by our core scientific expertise in creating and developing antibody, DART and TRIDENT™ therapeutics. The promising updates we provided on 11 of our programs today underscore the potential of our approach."
Program Updates and Highlights:
HER2 Franchise. MacroGenics provided an update regarding its most advanced franchise targeting the human epidermal growth factor receptor 2, or HER2, led by margetuximab, its Fc-optimized monoclonal antibody:
B7-H3 Franchise. MacroGenics highlighted its industry-leading franchise related to the therapeutic targeting of B7-H3, a member of the B7 family of molecules involved in immune regulation, that is broadly expressed in multiple solid tumors:
PD1-Directed Immuno-Oncology Franchise. MacroGenics introduced several new programs in its pipeline directed towards PD-1, which will enable both a broad set of combination opportunities across its portfolio and further differentiation from existing PD-1-based treatment options:
Update on DART Clinical Programs. Across its portfolio of clinical DART programs, the Company highlighted the promising features of its DART platform, including on-target engagement, manageable safety and preliminary evidence of biological activity. These DART programs include MGD009 and the following:
R&D Day Webcast
To view the recorded webcast of the Company's R&D Day event as well as download the presentation, please visit the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo, DART and TRIDENT are trademarks or registered trademarks of MacroGenics, Inc.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.
Contacts: Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, firstname.lastname@example.org Karen Sharma, Senior Vice President MacDougall Biomedical Communications 1-781-235-3060, email@example.com